The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | CheckMate 8HW: first-line nivolumab plus ipilimumab in MSI-H/dMMR mCRC
Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, comments on the expanded efficacy analysis from the Phase III CheckMate 8HW study (NCT04008030) of first-line nivolumab plus ipilimumab versus chemotherapy for patients with MSI-H/dMMR metastatic colorectal cancer (mCRC). Nivolumab and ipilimumab showed improved time to second objective disease progression (PFS2) and manageable safety profiles, reinforcing its role as a standard first-line treatment for MSI-H/dMMR mCRC. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role – 3T BioSciences; Bayer; BMS; Fulgent Genetics; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses – Bayer; BMS; Merck Serono
